Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis
Cancer Medicine · 2025
DOI: 10.1002/cam4.70601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Mio Takahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma, Endometrioid, Transcriptome, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Borderline ovarian tumors (BOTs) differ from ovarian carcinomas in their clinical presentation and behavior, yet their molecular characteristics remain poorly understood. This study aims to address this gap by integrating whole‐exome sequencing (WES) and RNA sequencing (RNA‐seq) to compare BOTs with high‐grade serous carcinoma (HGSC), endometrioid carcinoma (EC), and clear‐cell carcinoma (CCC).
Objective
To elucidate the molecular features of BOTs and evaluate their similarities and differences in comparison to HGSC, EC, and CCC.
Methods
The study analyzed 44 ovarian tumor samples, employing WES to identify genomic alterations and RNA‐seq to examine transcriptomic profiles. Comparative analyses were conducted to investigate the molecular relationships among the tumor types.
Results
The genomic analysis revealed that BOTs share significant similarities with EC. Furthermore, the transcriptomic data highlighted a novel and substantial similarity between BOTs and EC, suggesting deeper biological linkages, including potentially shared oncogenic pathways or tumor microenvironmental factors. These findings challenge traditional classifications and suggest a closer molecular alignment of BOTs with EC than previously understood.
Conclusions
This study provides new insights into the molecular characteristics of BOTs, demonstrating their significant resemblance to EC at both the genomic and transcriptomic levels. These results underscore the potential need to reconsider the molecular classification of ovarian tumors and open new avenues for research into the pathogenesis and treatment strategies for BOTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
- Center for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.
- Department of Biomedical Informatics, Communication Engineering Center, Electronic Systems Business Group, Mitsubishi Electric Software co. Ltd, Amagasaki, Hyogo, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Kagoshima, Japan.
ORCID-Profile: Kohei Nakamura, Tatsuyuki Chiyoda
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Takahashi, M., Nakamura, K., Chiyoda, T., Okada, C., Nohara, S., Takamatsu, R., Yanazume, S., Kobayashi, H., Nishihara, H., & Yamagami, W. (2025). Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70601
Vancouver
Takahashi M, Nakamura K, Chiyoda T, Okada C, Nohara S, Takamatsu R, et al. Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.70601
BibTeX
@article{Takahashi2025,
author = {Takahashi, Mio and Nakamura, Kohei and Chiyoda, Tatsuyuki and Okada, Chihiro and Nohara, Sachio and Takamatsu, Reika and Yanazume, Shintaro and Kobayashi, Hiroaki and Nishihara, Hiroshi and Yamagami, Wataru},
title = {Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70601}
}
EUVIMED